METASTATIC/LOCALLY ADVANCED POORLY DIFFERENTIATED NEC

Clinical trials for METASTATIC/LOCALLY ADVANCED POORLY DIFFERENTIATED NEC explained in plain language.

Never miss a new study

Get alerted when new METASTATIC/LOCALLY ADVANCED POORLY DIFFERENTIATED NEC trials appear

Sign up with your email to follow new studies for METASTATIC/LOCALLY ADVANCED POORLY DIFFERENTIATED NEC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug trial targets Tough-to-Treat lung cancers

Disease control Recruiting now

This study is testing an experimental drug called tarlatamab in patients with advanced small-cell lung cancer and other aggressive neuroendocrine cancers that have worsened after standard treatments. The main goal is to see how well the drug works and to understand why some patie…

Matched conditions: METASTATIC/LOCALLY ADVANCED POORLY DIFFERENTIATED NEC

Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control

Last updated Mar 09, 2026 14:24 UTC

METASTATIC/LOCALLY ADVANCED POORLY DIFFERENTIATED NEC

Get alerted when new METASTATIC/LOCALLY ADVANCED POORLY DIFFERENTIATED NEC trials appear

New drug trial targets Tough-to-Treat lung cancers